JOP20220227A1 - مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة - Google Patents
مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِةInfo
- Publication number
- JOP20220227A1 JOP20220227A1 JOP/2022/0227A JOP20220227A JOP20220227A1 JO P20220227 A1 JOP20220227 A1 JO P20220227A1 JO P20220227 A JOP20220227 A JO P20220227A JO P20220227 A1 JOP20220227 A1 JO P20220227A1
- Authority
- JO
- Jordan
- Prior art keywords
- inhibitors
- pyrrolopyrimidine
- complement
- amines
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- -1 Pyrrolopyrimidine amines Chemical class 0.000 title 1
- 230000000295 complement effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000004154 complement system Effects 0.000 abstract 2
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063004799P | 2020-04-03 | 2020-04-03 | |
| PCT/US2021/025547 WO2021202977A1 (en) | 2020-04-03 | 2021-04-02 | Pyrrolopyrimidine amines as complement inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20220227A1 true JOP20220227A1 (ar) | 2023-01-30 |
Family
ID=77929437
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2022/0227A JOP20220227A1 (ar) | 2020-04-03 | 2021-04-02 | مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة |
| JOJO/P/2022/0228A JOP20220228A1 (ar) | 2020-04-03 | 2022-09-22 | مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2022/0228A JOP20220228A1 (ar) | 2020-04-03 | 2022-09-22 | مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20230159536A1 (https=) |
| EP (1) | EP4125914A4 (https=) |
| JP (2) | JP7763772B2 (https=) |
| KR (1) | KR20220163955A (https=) |
| CN (1) | CN115427044A (https=) |
| AR (1) | AR121715A1 (https=) |
| AU (1) | AU2021246098A1 (https=) |
| BR (1) | BR112022018067A2 (https=) |
| CA (1) | CA3176808A1 (https=) |
| CL (1) | CL2022002649A1 (https=) |
| CO (1) | CO2022015630A2 (https=) |
| CR (1) | CR20220553A (https=) |
| CU (1) | CU20220060A7 (https=) |
| DO (2) | DOP2022000211A (https=) |
| EC (1) | ECSP22085221A (https=) |
| GE (1) | GEP20257841B (https=) |
| IL (1) | IL296978A (https=) |
| JO (2) | JOP20220227A1 (https=) |
| MX (1) | MX2022012056A (https=) |
| PE (1) | PE20230601A1 (https=) |
| PY (1) | PY2126225A (https=) |
| TN (1) | TN2022000255A1 (https=) |
| TW (1) | TWI912303B (https=) |
| UY (1) | UY39150A (https=) |
| WO (1) | WO2021202977A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023069301A1 (en) * | 2021-10-18 | 2023-04-27 | Alexion Pharmaceuticals, Inc. | Use of complement factor d inhibitor for treatment of lupus nephritis and immunoglobulin a nephropathy |
| WO2024008121A1 (zh) * | 2022-07-06 | 2024-01-11 | 南京明德新药研发有限公司 | 二氟取代的氮杂双环化合物及其应用 |
| JP2025530036A (ja) * | 2022-09-01 | 2025-09-10 | エフ． ホフマン－ラ ロシュ アーゲー | ビカシナビンの投与レジメン |
| US11945818B1 (en) | 2023-09-06 | 2024-04-02 | King Faisal University | Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors |
| US11964981B1 (en) | 2023-09-18 | 2024-04-23 | King Faisal University | Substituted pyrimido[4,5-b]indoles as CK2 inhibitors |
| WO2025217212A1 (en) * | 2024-04-09 | 2025-10-16 | The Regents Of The University Of California | Mac1 inhibitors and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
| US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| DE69110787T2 (de) | 1990-02-28 | 1996-04-04 | Medtronic, Inc., Minneapolis, Minn. | Intraluminale prothese mit wirkstoffeluierung. |
| US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
| US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
| US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
| IL123986A (en) * | 1997-04-24 | 2011-10-31 | Organon Nv | Medicinal compounds |
| JPH11292840A (ja) * | 1998-04-06 | 1999-10-26 | Soyaku Gijutsu Kenkyusho:Kk | ノルスタチン誘導体又はその塩 |
| EP1144373B1 (en) | 1999-01-13 | 2005-10-19 | Genentech, Inc. | Serine protease inhibitors |
| US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
| PT2661433T (pt) | 2011-01-04 | 2017-10-24 | Novartis Ag | Compostos de indole ou seus análogos úteis para o tratamento da degeneração macular relacionada com a idade (amd) |
| CN104379579B (zh) | 2012-06-28 | 2017-03-08 | 诺华股份有限公司 | 吡咯烷衍生物及其作为补体途径调节剂的用途 |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035348A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Alkyne compounds for treatment of medical disorders |
| AR105809A1 (es) * | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
| US10385097B2 (en) | 2015-08-26 | 2019-08-20 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
| TWI747873B (zh) | 2016-02-01 | 2021-12-01 | 美商百歐克斯製藥公司 | 苯并吡唑化合物及其類似物 |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| WO2018229543A2 (en) | 2017-06-14 | 2018-12-20 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| TWI873092B (zh) | 2018-04-06 | 2025-02-21 | 美商百歐克斯製藥公司 | 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑 |
-
2021
- 2021-03-31 AR ARP210100817A patent/AR121715A1/es unknown
- 2021-04-01 TW TW110112139A patent/TWI912303B/zh active
- 2021-04-02 BR BR112022018067A patent/BR112022018067A2/pt unknown
- 2021-04-02 GE GEAP202116073A patent/GEP20257841B/en unknown
- 2021-04-02 KR KR1020227033595A patent/KR20220163955A/ko active Pending
- 2021-04-02 JP JP2022556491A patent/JP7763772B2/ja active Active
- 2021-04-02 PE PE2022002121A patent/PE20230601A1/es unknown
- 2021-04-02 CN CN202180025930.0A patent/CN115427044A/zh active Pending
- 2021-04-02 AU AU2021246098A patent/AU2021246098A1/en active Pending
- 2021-04-02 TN TNP/2022/000255A patent/TN2022000255A1/en unknown
- 2021-04-02 MX MX2022012056A patent/MX2022012056A/es unknown
- 2021-04-02 JO JOP/2022/0227A patent/JOP20220227A1/ar unknown
- 2021-04-02 EP EP21781014.2A patent/EP4125914A4/en active Pending
- 2021-04-02 CR CR20220553A patent/CR20220553A/es unknown
- 2021-04-02 CU CU2022000060A patent/CU20220060A7/es unknown
- 2021-04-02 CA CA3176808A patent/CA3176808A1/en active Pending
- 2021-04-02 WO PCT/US2021/025547 patent/WO2021202977A1/en not_active Ceased
- 2021-04-02 US US17/915,179 patent/US20230159536A1/en active Pending
- 2021-04-02 IL IL296978A patent/IL296978A/en unknown
- 2021-04-05 PY PY202102126225A patent/PY2126225A/es unknown
- 2021-04-05 UY UY0001039150A patent/UY39150A/es unknown
-
2022
- 2022-09-22 JO JOJO/P/2022/0228A patent/JOP20220228A1/ar unknown
- 2022-09-28 DO DO2022000211A patent/DOP2022000211A/es unknown
- 2022-09-28 CL CL2022002649A patent/CL2022002649A1/es unknown
- 2022-10-31 CO CONC2022/0015630A patent/CO2022015630A2/es unknown
- 2022-11-02 EC ECSENADI202285221A patent/ECSP22085221A/es unknown
-
2025
- 2025-02-26 DO DO2025000044A patent/DOP2025000044A/es unknown
- 2025-10-22 JP JP2025177542A patent/JP2026009184A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2022000211A (es) | 2022-11-15 |
| PE20230601A1 (es) | 2023-04-10 |
| PY2126225A (es) | 2022-10-31 |
| CO2022015630A2 (es) | 2022-11-29 |
| CN115427044A (zh) | 2022-12-02 |
| CL2022002649A1 (es) | 2023-05-26 |
| MX2022012056A (es) | 2022-10-13 |
| JP2026009184A (ja) | 2026-01-19 |
| AR121715A1 (es) | 2022-06-29 |
| CR20220553A (es) | 2023-02-03 |
| JOP20220228A1 (ar) | 2022-09-22 |
| DOP2025000044A (es) | 2025-04-08 |
| UY39150A (es) | 2021-10-29 |
| EP4125914A1 (en) | 2023-02-08 |
| KR20220163955A (ko) | 2022-12-12 |
| TW202204358A (zh) | 2022-02-01 |
| US20230159536A1 (en) | 2023-05-25 |
| CA3176808A1 (en) | 2021-10-07 |
| JP7763772B2 (ja) | 2025-11-04 |
| GEP20257841B (en) | 2025-12-25 |
| ECSP22085221A (es) | 2022-12-30 |
| BR112022018067A2 (pt) | 2022-10-25 |
| EP4125914A4 (en) | 2024-07-03 |
| WO2021202977A1 (en) | 2021-10-07 |
| IL296978A (en) | 2022-12-01 |
| TN2022000255A1 (en) | 2024-04-01 |
| TWI912303B (zh) | 2026-01-21 |
| CU20220060A7 (es) | 2023-05-11 |
| JP2023519824A (ja) | 2023-05-15 |
| AU2021246098A1 (en) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220227A1 (ar) | مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2021009276A (es) | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2. | |
| MX2022007915A (es) | Compuestos de benzopirazol y analogos de estos. | |
| EA202092383A1 (ru) | Ингибиторы комплемента на основе замещенного бензофурана, бензопиррола, бензотиофена и их структурных производных | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| CL2024000067A1 (es) | Compuestos antivirales | |
| TN2022000092A1 (en) | Oral complement factor d inhibitors | |
| MX2026001199A (es) | Inhibidores del factor d del complemento para administracion oral | |
| PH12021552201A1 (en) | Benzodiazepine derivatives as rsv inhibitors | |
| GEAP202516634A (en) | Heteroaryl compounds for the treatment of pain | |
| PH12023552856A1 (en) | Bicyclic heteroaromatic inhibitors of klk5 | |
| BR112021025618A2 (pt) | Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto | |
| GEAP202516217A (en) | Compounds and compositions as sppl2a inhibitors | |
| JOP20250073A1 (ar) | مركبات سلفوكسيمين كمثبط دياسيتيلاز هيستون 6، وتركيبة صيدلانية تشتمل عليها | |
| EA202192511A1 (ru) | Бензодиазепиновые производные в качестве ингибиторов рсв |